14-day Premium Trial Subscription Sign Up For FreeGet Free

$3.76 (0%)

Volume: 0

Closed: Jan 19, 2022

Hollow Logo Score: 0.000

Chiasma Stock Forecast

$3.76 (0%)

Volume: 0

Closed: Jan 19, 2022

Score Hollow Logo 0.000

Chiasma Company Profile

60 Wells Avenue

Newton MA 02459



Industry: Biotechnology

Sector: Healthcare



Chiasma, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing oral forms of therapies for patients suffering from orphan diseases. Its product candidate is octreotide capsules or MYCAPSSA, which has completed Phase III clinical trial for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone. Chiasma, Inc. was founded in 2001 and is headquartered in Newton, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE